RxDoctor Payments Data

Grace Herwig

Psychiatric/Mental Health, Adult · Westlake, OHNPI 1740476548

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 27.2% of the total.

$3,815in general payments, 2019–2025

Across 38 payments — averaging $100.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Axsome Therapeutics, Inc.$670
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$582
  • Otsuka America Pharmaceutical, Inc.$452
  • E.r. Squibb & Sons, L.L.C.$379
  • Johnson & Johnson$375
  • plus $319 from 2 others

What the payments were for

  • Food & beverage$3,78799%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,815 in reported general payments places this provider in the 80th percentile of 42 psychiatric/mental health, adult providers in Ohio.

See all psychiatric/mental health, adult providers in Ohio

Medicare billing

Part B allowed, 2024
$15,465
Medicare patients
21
Services billed
200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole17$21,796
Lurasidone Hcl80$20,379
Clozapine25$1,774
Bupropion XlBupropion Hcl47$1,175
Buspirone Hcl82$1,140
Vilazodone Hcl19$1,114
Desvenlafaxine Succinate ErDesvenlafaxine Succinate16$799
Venlafaxine Hcl ErVenlafaxine Hcl26$790
Aripiprazole28$767
Prazosin Hcl29$744
Alprazolam79$711
Clonazepam124$570
Duloxetine Hcl58$559
Lamotrigine86$543
Escitalopram Oxalate54$537

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$452$21,79617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 42 psychiatric/mental health, adult providers in Ohio.

Other psychiatric/mental health, adult in Westlake

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →